UBS Group
CCCC icon

UBS Group’s C4 Therapeutics CCCC Stock Holding History

UBS Group’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-30,000
Closed -$226K – 10372
2022
Q2 		$226K Buy
+30,000
New +$264K ﹤0.01% 4815

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group's CCCC Position: Q1 2026 in Review

UBS Group increased its C4 Therapeutics (CCCC) stake by 309% in Q1 2026, buying an estimated $384K and bringing the position to 215,877 shares worth $568K. The position accounts for ﹤0.01% of the portfolio, ranked #5995.

UBS Group first reported a position in CCCC in Q4 2020 and has held it in 22 quarters since. The position peaked at $18.6M in Q3 2021. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • UBS Group held 215,877 shares of C4 Therapeutics worth $568K as of Q1 2026.
  • UBS Group bought 163,125 C4 Therapeutics shares in Q1 2026, an estimated $384K.
  • C4 Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5995 holding.
  • UBS Group first reported a position in C4 Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • UBS Group's C4 Therapeutics position peaked at $18.6M in Q3 2021.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.